Active Ingredient(s): Dolutegravir + Rilpivirine
FDA Approved: * November 21, 2017
Pharm Company: * VIIV HLTHCARE
Category: HIV / AIDS

* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".

Juluca Overview

Dolutegravir (DTG) is a medication used for the treatment of HIV infection. Dolutegravir is an integrase inhibitor. The drug is marketed as Tivicay[2] by GlaxoSmithKline (GSK). In February, 2013 the Food and Drug Administration announced that it would fast track dolutegravir's approval process.[3] On August 13, 2013, dolutegravir was approved by the FDA. On November 4, 2013, dolutegravir was approved by Health Canada.[4] On January 16, 2014, it was approved by the European Commission for use ...

Read more Juluca Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Dolutegravir

Recent Juluca Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

Dolutegravir + Rilpivirine
  • Tablet: 50mg + 25mg
Note: Above list includes dosages for all drugs with the same combination of active ingredients.

NDC Database Records for Juluca: (1 result)

Sorted by National Drug Code
  • 49702-242 Juluca Oral Tablet, Film Coated by Viiv Healthcare Company

Drugs with one or more similar ingredients: (11 results)

Note: All times displayed are GMT - 7.

This information has been independently compiled and is for informational purposes only. It is not intended to be a substitute for medical advice from a qualified healthcare professional; nor is it intended to diagnose, treat, cure or prevent any disease. For more details please see the Medical Disclaimer. Site content is Copyright © 2005-2018 MedsChat.com and is protected under U.S. and International Copyright laws. All Rights Reserved. This page was last updated on 17 March 2018.

We are committed to your privacy.

Copyright © 2005-2018 All Rights Reserved. MedsChat® and The People's Medicine Community® are registered trademarks of Limelight Innovations L.L.C.